Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

SOPHiA GENETICS SA SOPH

Healthcare  —  Health Information Services
8.34 0.08 0.97% as of 25 Sep
Market cap
$703.2M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

SOPHiA GENETICS SA (SOPH) Business Profile

Updated before January 2025

Company Overview

SOPHiA GENETICS SA (NASDAQ: SOPH) is a global leader in data-driven medicine, leveraging advanced artificial intelligence (AI) and machine learning (ML) technologies to empower healthcare professionals with actionable insights. Founded in 2011 by Dr. Jurgi Camblong, Dr. Lars Steinmetz, and Pierre Hutter, the company is headquartered in Saint-Sulpice, Switzerland, with additional offices in the United States and other global locations. SOPHiA GENETICS operates under the leadership of Dr. Jurgi Camblong, who serves as the Chief Executive Officer (CEO), and a team of seasoned executives with expertise in genomics, data science, and healthcare innovation.

The company was established with the mission of democratizing data-driven medicine by making complex genomic and clinical data accessible and interpretable for healthcare providers worldwide. SOPHiA GENETICS has since grown into a trusted partner for hospitals, laboratories, and research institutions, serving clients in over 70 countries.

Core Business Segments

SOPHiA GENETICS operates across several core business segments, offering a range of products and services designed to enhance precision medicine and improve patient outcomes. These segments include:

1. SOPHiA DDM™ Platform

The SOPHiA DDM™ (Data-Driven Medicine) platform is the company’s flagship product. It is a cloud-based software-as-a-service (SaaS) platform that integrates genomic and clinical data to provide actionable insights for healthcare professionals. Key features include:

  • Genomic Analysis: Enables the analysis of next-generation sequencing (NGS) data for various applications, including oncology, hereditary disorders, and rare diseases.
  • Clinical Decision Support: Provides advanced algorithms and AI-driven insights to assist in clinical decision-making.
  • Scalability: Designed to support institutions of all sizes, from small laboratories to large healthcare networks.

2. Oncology Solutions

SOPHiA GENETICS offers specialized solutions for oncology, focusing on cancer diagnostics and treatment planning. These include:

  • Comprehensive Genomic Profiling: Tools for identifying genetic mutations and biomarkers associated with cancer.
  • Liquid Biopsy Analysis: Non-invasive testing methods for detecting cancer-related genetic alterations.
  • Therapeutic Matching: AI-driven recommendations for targeted therapies based on genomic data.

3. Hereditary Disorders and Rare Diseases

The company provides solutions for diagnosing hereditary disorders and rare diseases, leveraging its expertise in genomic data analysis. These solutions help identify genetic mutations that may contribute to conditions such as cystic fibrosis, muscular dystrophy, and other inherited diseases.

4. Partnerships and Custom Solutions

SOPHiA GENETICS collaborates with pharmaceutical companies, research institutions, and healthcare providers to develop custom solutions tailored to specific needs. These partnerships often focus on:

  • Clinical Trials: Supporting drug development and biomarker discovery.
  • Data Integration: Combining genomic data with other clinical datasets for comprehensive analysis.

Business Model

SOPHiA GENETICS operates on a subscription-based business model, primarily generating revenue through its SOPHiA DDM™ platform. Key aspects of the business model include:

  • SaaS Revenue: Clients pay subscription fees to access the SOPHiA DDM™ platform, which includes data analysis, storage, and reporting capabilities.
  • Partnership Revenue: The company collaborates with pharmaceutical companies and research institutions, generating revenue through joint projects and custom solutions.
  • Scalable Infrastructure: The cloud-based nature of the platform allows SOPHiA GENETICS to scale its services efficiently, catering to a diverse range of clients.

Strategic Direction

SOPHiA GENETICS is focused on expanding its global footprint and enhancing its product offerings. Key strategic priorities include:

  • Platform Expansion: Continuously improving the SOPHiA DDM™ platform by integrating new data types, algorithms, and features.
  • Geographic Growth: Expanding operations in emerging markets, particularly in Asia-Pacific and Latin America.
  • Sustainability Goals: Committing to environmentally sustainable practices in its operations and supply chain.
  • New Product Categories: Exploring opportunities in areas such as proteomics, metabolomics, and digital pathology.

Competitive Landscape

SOPHiA GENETICS operates in a highly competitive market, facing competition from companies in genomics, bioinformatics, and healthcare IT. Key competitors include:

  • Illumina, Inc.: A leader in genomic sequencing technologies.
  • Thermo Fisher Scientific: Offers a range of genomic analysis tools and services.
  • Foundation Medicine: Specializes in comprehensive genomic profiling for oncology.
  • Qiagen: Provides molecular diagnostics and bioinformatics solutions.
  • Tempus: Focuses on AI-driven precision medicine and data analytics.

Despite the competition, SOPHiA GENETICS differentiates itself through its platform-agnostic approach, enabling compatibility with various sequencing technologies and data sources.

Risk Factors

SOPHiA GENETICS faces several risks that could impact its business operations and financial performance. These include:

  • Market Dependence: Reliance on the adoption of genomic and precision medicine technologies by healthcare providers.
  • Regulatory Challenges: Compliance with healthcare regulations and data privacy laws in multiple jurisdictions.
  • Supply Chain Disruptions: Potential disruptions in the supply of reagents, equipment, and other critical inputs.
  • Competition: Intense competition from established players and new entrants in the genomics and bioinformatics sectors.
  • Economic Conditions: Global economic uncertainties that may affect healthcare budgets and spending.

Recent Developments

SOPHiA GENETICS has made significant strides in recent years, including:

  • Product Innovations: Launching new features and capabilities for the SOPHiA DDM™ platform, such as expanded support for liquid biopsy analysis.
  • Strategic Partnerships: Collaborating with leading pharmaceutical companies to support clinical trials and drug development.
  • Global Expansion: Opening new offices and strengthening its presence in key markets, including the United States and Asia-Pacific.
  • COVID-19 Response: Adapting its platform to support research and diagnostics related to the COVID-19 pandemic.

Investment Considerations

Investors considering SOPHiA GENETICS should weigh the following factors:

Strengths

  • Innovative Technology: A cutting-edge platform that integrates AI and genomic data.
  • Global Reach: A strong presence in over 70 countries.
  • Scalable Business Model: Subscription-based revenue with significant growth potential.

Risks

  • Market Volatility: Dependence on the adoption of precision medicine technologies.
  • Regulatory Risks: Compliance challenges in multiple jurisdictions.
  • Competitive Pressure: Intense competition from established players.

Conclusion

SOPHiA GENETICS is a pioneering company at the forefront of data-driven medicine, offering innovative solutions that empower healthcare providers and improve patient outcomes. With a robust platform, a scalable business model, and a commitment to innovation, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with market adoption, regulatory compliance, and competition. Overall, SOPHiA GENETICS represents a compelling opportunity in the rapidly evolving field of precision medicine.